Cannabinoids and emotionality: A neuroanatomical perspective

Neuroscience

Volumn 204, Issue , 2012, Pages 134-144

  McLaughlin, R J ^a,b   Gobbi, G ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cannabinoid; Corticolimbic network; Emotional behavior; Microinfusion; Rat; Stress

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE;

ASSOCIATIVE MEMORY; BASOLATERAL AMYGDALA; BRAIN FUNCTION; BRAIN REGION; CENTRAL NUCLEUS (AMYGDALA); CHRONIC STRESS; EMOTIONAL DISORDER; EMOTIONALITY; HIPPOCAMPUS; HUMAN; LIMBIC CORTEX; NEUROANATOMY; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

AMYGDALA; ANIMALS; EMOTIONS; ENDOCANNABINOIDS; HIPPOCAMPUS; PREFRONTAL CORTEX;

EID: 84857128132     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.07.052     Document Type: Review

References (127)

1. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008, 59:217-228.
2. Aguado T., Monory K., Palazuelos J., Stella N., Cravatt B., Lutz B., et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005, 19:1704-1706.
3. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108:1687-1707.
4. Amat J., Baratta M.V., Paul E., Bland S.T., Watkins L.R., Maier S.F. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 2005, 8:365-371.
5. Aso E., Ozaita A., Valdizán E.M., Ledent C., Pazos A., Maldonado R., et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008, 105:565-572.
6. Azad S.C., Eder M., Marsicano G., Lutz B., Zieglgänsberger W., Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 2003, 10:116-128.
7. Azad S.C., Kurz J., Marsicano G., Lutz B., Zieglgänsberger W., Rammes G. Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learn Mem 2008, 15:143-152.
8. Azad S.C., Monory K., Marsicano G., Cravatt B.F., Lutz B., Zieglgänsberger W., et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 2004, 24:9953-9961.
9. Bambico F.R., Cassano T., Dominguez-Lopez S., Katz N., Walker C.D., Piomelli D., et al. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35:2083-2100.
10. Bambico F.R., Duranti A., Tontini A., Tarzia G., Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 2009, 15:1623-1646.
11. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
12. Barna I., Zelena D., Arszovszki A.C., Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004, 75:2959-2970.
13. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010, 39:148-155.
14. Bonne O., Vythilingam M., Inagaki M., Wood S., Neumeister A., Nugent A.C., et al. Reduced posterior hippocampal volume in posttraumatic stress disorder. J Clin Psychiatry 2008, 69:1087-1091.
15. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006, 31:2652-2659.
16. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62:1103-1110.
17. Braida D., Limonta V., Malabarba L., Zani A., Sala M. 5-HT1A receptors are involved in the anxiolytic effect of delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007, 555:156-163.
18. Campos A.C., Ferreira F.R., Guimarães F.S., Lemos J.I. Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 2010, 167:238-246.
19. Cassano T., Gaetani S., Macheda T., Laconca L., Romano A., Morgese M.G., et al. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology (Berl) 2011, 214:465-476.
20. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A.V. [A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant]. Ugeskr Laeger 2007, 169:4360-4363.
21. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
22. Curran H.V., Brignell C., Fletcher S., Middleton P., Henry J. Cognitive and subjective dose-response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 2002, 164:61-70.
23. de Oliveira Alvares L., Engelke D.S., Diehl F., Scheffer-Teixeira R., Haubrich J., de Freitas Cassini L., et al. Stress response recruits the hippocampal endocannabinoid system for the modulation of fear memory. Learn Mem 2010, 17:202-209.
24. Dedovic K., Duchesne A., Andrews J., Engert V., Pruessner J.C. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage 2009, 47:864-871.
25. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
26. Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.U., et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006, 26:5794-5799.
27. Drevets W.C. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci 2007, 1121:499-527.
28. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118.
29. Drevets W.C., Price J.L., Simpson J.R., Todd R.D., Reich T., Vannier M., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
30. Eisenstein S.A., Clapper J.R., Holmes P.V., Piomelli D., Hohmann A.G. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacol Res 2010, 61:419-429.
31. Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65:7-19.
32. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
33. Frey B.N., Andreazza A.C., Nery F.G., Martins M.R., Quevedo J., Soares J.C., et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 2007, 18:419-430.
34. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
35. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 2005, 102:18620-18625.
36. Goldman-Rakic P.S., Selemon L.D., Schwartz M.L. Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey. Neuroscience 1984, 12:719-743.
37. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005, 57:261-267.
38. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
39. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004, 19:1906-1912.
40. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
41. Hamani C., Diwan M., Isabella S., Lozano A.M., Nobrega J.N. Effects of different stimulation parameters on the antidepressant-like response of medial prefrontal cortex deep brain stimulation in rats. J Psychiatr Res 2010, 44:683-687.
42. Hamani C., Diwan M., Macedo C.E., Brandao M.L., Shumake J., Gonzalez-Lima F., et al. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry 2010, 67:117-124.
43. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 1992, 654:19-32.
44. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
45. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
46. Herman J.P., Figueiredo H., Mueller N.K., Ulrich-Lai Y., Ostrander M.M., Choi D.C., et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol 2003, 24:151-180.
47. Hill M.N., Carrier E.J., Ho W.S., Shi L., Patel S., Gorzalka B.B., et al. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hippocampus 2008, 18:221-226.
48. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106:2322-2336.
49. Hill M.N., Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol 2005, 16:333-352.
50. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15:593-599.
51. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 2009, 8:451-458.
52. Hill M.N., Gorzalka B.B. Impairments in endocannabinoid signaling and depressive illness. JAMA 2009, 301:1165-1166.
53. Hill MN, Hillard CJ, McEwen BS (in press) Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress. Cereb Cortex, in press.
54. Hill M.N., Hunter R.G., McEwen B.S. Chronic stress differentially regulates cannabinoid CB1 receptor binding in distinct hippocampal subfields. Eur J Pharmacol 2009, 614:66-69.
55. Hill M.N., Karacabeyli E.S., Gorzalka B.B. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007, 32:350-357.
56. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T., Gray J.M., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010, 107:9406-9411.
57. Hill M.N., McLaughlin R.J., Pan B., Fitzgerald M.L., Roberts C.J., Lee T.T., et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 2011, 31:10506-10515.
58. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
59. Hu W., Zhang M., Czeh B., Zhang W., Flugge G. Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. Brain Res Bull 2011, 85:374-379.
60. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004, 9:184-190.
61. Jacobson L., Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991, 12:118-134.
62. Jankord R., Herman J.P. Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. Ann N Y Acad Sci 2008, 1148:64-73.
63. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115:3104-3116.
64. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 2004, 66:204-208.
65. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9:76-81.
66. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008, 14:923-930.
67. Krettek J.E., Price J.L. Projections from the amygdaloid complex and adjacent olfactory structures to the entorhinal cortex and to the subiculum in the rat and cat. J Comp Neurol 1977, 172:723-752.
68. Krettek J.E., Price J.L. Projections from the amygdaloid complex to the cerebral cortex and thalamus in the rat and cat. J Comp Neurol 1977, 172:687-722.
69. Lafourcade M., Larrieu T., Mato S., Duffaud A., Sepers M., Matias I., et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 2011, 14:345-350.
70. Laviolette S.R., Grace A.A. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J Neurosci 2006, 26:6458-6468.
71. Laviolette S.R., Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 2006, 63:1597-1613.
72. Laviolette S.R., Lipski W.J., Grace A.A. A subpopulation of neurons in the medial prefrontal cortex encodes emotional learning with burst and frequency codes through a dopamine D4 receptor-dependent basolateral amygdala input. J Neurosci 2005, 25:6066-6075.
73. Lemos J.I., Resstel L.B., Guimarães F.S. Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behav Brain Res 2010, 207:105-111.
74. Lin H.C., Mao S.C., Gean P.W. Effects of intra-amygdala infusion of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn Mem 2006, 13:316-321.
75. Lin H.C., Mao S.C., Su C.L., Gean P.W. The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 2009, 19:165-175.
76. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2011, 16:252-264.
77. Maier S.F., Amat J., Baratta M.V., Paul E., Watkins L.R. Behavioral control, the medial prefrontal cortex, and resilience. Dialogues Clin Neurosci 2006, 8:397-406.
78. Maisonnette S., Morato S., Brandão M.L. Role of resocialization and of 5-HT1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test. Physiol Behav 1993, 54:753-758.
79. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
80. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159:379-387.
81. Mato S., Pazos A. Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 2004, 46:716-726.
82. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
83. McLaughlin K.J., Baran S.E., Conrad C.D. Chronic stress- and sex-specific neuromorphological and functional changes in limbic structures. Mol Neurobiol 2009, 40:166-182.
84. McLaughlin R.J., Hill M.N., Morrish A.C., Gorzalka B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007, 18:431-438.
85. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
86. Moise A.M., Eisenstein S.A., Astarita G., Piomelli D., Hohmann A.G. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 2008, 200:333-346.
87. Moreira F.A., Kaiser N., Monory K., Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
88. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010, 2:429-450.
89. Naderi N., Haghparast A., Saber-Tehrani A., Rezaii N., Alizadeh A.M., Khani A., et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008, 89:64-75.
90. Naidu P.S., Varvel S.A., Ahn K., Cravatt B.F., Martin B.R., Lichtman A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007, 192:61-70.
91. Navarro M., Hernández E., Muñoz R.M., del Arco I., Villanúa M.A., Carrera M.R., et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997, 8:491-496.
92. Nissen S.E., Nicholls S.J., Wolski K., Rodés-Cabau J., Cannon C.P., Deanfield J.E., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
93. Ongür D., Ferry A.T., Price J.L. Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comp Neurol 2003, 460:425-449.
94. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.
95. Petrovich G.D., Canteras N.S., Swanson L.W. Combinatorial amygdalar inputs to hippocampal domains and hypothalamic behavior systems. Brain Res Brain Res Rev 2001, 38:247-289.
96. Poncelet M., Maruani J., Calassi R., Soubrié P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003, 343:216-218.
97. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
98. Rajkowska G. Morphometric methods for studying the prefrontal cortex in suicide victims and psychiatric patients. Ann N Y Acad Sci 1997, 836:253-268.
99. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
100. Realini N., Vigano' D., Guidali C., Zamberletti E., Rubino T., Parolaro D. Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 2011, 60:235-243.
101. Roche M., O'Connor E., Diskin C., Finn D.P. The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. Eur J Neurosci 2007, 26:2643-2653.
102. Rodríguez-Gaztelumendi A., Rojo M.L., Pazos A., Díaz A. Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 2009, 108:1423-1433.
103. Roohbakhsh A., Keshavarz S., Hasanein P., Rezvani M.E., Moghaddam A.H. Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol 2009, 105:333-338.
104. Roohbakhsh A., Moghaddam A.H., Massoudi R., Zarrindast M.R. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 2007, 34:223-229.
105. Rosenkranz J.A., Grace A.A. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci 2002, 22:324-337.
106. Rosenkranz J.A., Grace A.A. Affective conditioning in the basolateral amygdala of anesthetized rats is modulated by dopamine and prefrontal cortical inputs. Ann N Y Acad Sci 2003, 985:488-491.
107. Rossi S., De Chiara V., Musella A., Sacchetti L., Cantarella C., Castelli M., et al. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol Pharmacol 2010, 78:260-268.
108. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
109. Rubino T., Realini N., Castiglioni C., Guidali C., Vigano D., Marras E., et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008, 18:1292-1301.
110. Rutkowska M., Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004, 61:165-167.
111. Rutkowska M., Jamontt J., Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 2006, 58:200-206.
112. Sah P., Lopez De Armentia M. Excitatory synaptic transmission in the lateral and central amygdala. Ann N Y Acad Sci 2003, 985:67-77.
113. Sanchis-Segura C., Cline B.H., Marsicano G., Lutz B., Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 2004, 176:223-232.
114. Scherma M., Medalie J., Fratta W., Vadivel S.K., Makriyannis A., Piomelli D., et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008, 54:129-140.
115. Segev A., Akirav I. Differential effects of cannabinoid receptor agonist on social discrimination and contextual fear in amygdala and hippocampus. Learn Mem 2011, 18:254-259.
116. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003, 14:573-582.
117. Shin L.M., Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010, 35:169-191.
118. Sibille E., Wang Y., Joeyen-Waldorf J., Gaiteri C., Surget A., Oh S., et al. A molecular signature of depression in the amygdala. Am J Psychiatry 2009, 166:1011-1024.
119. Siegel A., Tassoni J.P. Differential efferent projections from the ventral and dorsal hippocampus of the cat. Brain Behav Evol 1971, 4:185-200.
120. Steiner M.A., Marsicano G., Nestler E.J., Holsboer F., Lutz B., Wotjak C.T. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008, 33:54-67.
121. Steiner M.A., Wanisch K., Monory K., Marsicano G., Borroni E., Bachli H., et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 2008, 8:196-208.
122. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
123. Tan H., Lauzon N.M., Bishop S.F., Bechard M.A., Laviolette S.R. Integrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encoding. Cereb Cortex 2010, 20:1486-1496.
124. Tan H., Lauzon N.M., Bishop S.F., Chi N., Bechard M., Laviolette S.R. Cannabinoid transmission in the basolateral amygdala modulates fear memory formation via functional inputs to the prelimbic cortex. J Neurosci 2011, 31:5300-5312.
125. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007, 32:1032-1041.
126. Vinod K.Y., Arango V., Xie S., Kassir S.A., Mann J.J., Cooper T.B., et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 2005, 57:480-486.
127. Zarrindast M.R., Sarahroodi S., Arzi A., Khodayar M.J., Taheri-Shalmani S., Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 2008, 19:716-723.